Komiyama N, Tame J, Nagai K
MRC Laboratory of Molecular Biology, Cambridge, U.K.
Biol Chem. 1996 Sep;377(9):543-8. doi: 10.1515/bchm3.1996.377.9.543.
Recombinant DNA technology has enabled the large scale production of human hemoglobin in bacteria and yeast. This has opened up a way to produce a hemoglobin-based blood substitute which could replace conventional blood transfusion in some situations. Using our understanding of the structure-function relationships and evolutionary history of hemoglobin it has been possible to improve the oxygen transport properties of the molecule and solve a number of problems associated with the use of natural hemoglobin as a cell-free blood substitute.
重组DNA技术已能够在细菌和酵母中大规模生产人血红蛋白。这开辟了一条生产基于血红蛋白的血液替代品的途径,该替代品在某些情况下可替代传统输血。利用我们对血红蛋白结构 - 功能关系和进化史的了解,已能够改善该分子的氧运输特性,并解决与使用天然血红蛋白作为无细胞血液替代品相关的一些问题。